Hoffmann-la Roche Inc.

Janssen Pharmaceutica Nv

Beijing Hawaga Power Storage Technology Company Ltd.

Heibei May Joy Battery Company Ltd.

Suzhou Yunxuan Yiyao Keji Youxian Gongsi

F. Hoffmann-la Roche Ag

Xiaohu Zhang

Matthew C Lucas

Kin-Chun Thomas Luk

Johannes Cornelius Hermann

Fernando Padilla

Ronald L Wolin

Jianmei Wei

Brad M Savall

Steven P Meduna

Hui Cai

Kevin L Tays

Robin L Thurmond

Frank Chavez

Jutta Wanner

Paul J Dunford

Andrew J Greenspan

Jorge A Quiroz

Ping Zhang

Bin Zhang

Matthew Michael Hamilton

Ce Wang

Javier De Vicente Fidalgo

Achyutharao Sidduri

Michael Soth

Peter Michael Wovkulich

Ryan Craig Schoenfeld

Allen John Lovey

Shaoqing Chen

Stephen Matthew Lynch

Hongju Li

Yanping Zhang

Joshua Jahmil Kennedy-Smith

Andreas Kuglstatter

Joshua Kennedy-Smith

Wenjian Liu

Yongchong Chen

Wenwei Xie

Yingyuan He

Caimei Feng

Counde O'yang

Lee Edwin Lowrie, Jr

Stephen M Lynch

Jr Lee Edwin Lowrie

Provided is a no-liquid cell-core for a lithium slurry battery. The no-liquid cell-core comprises multiple positive electrode pieces and negative electrode pieces overlapping alternately. The positive electrode piece comprises an electric-conductive cathode layer and a cathode surface current-collecting layer, wherein the electric-conductive cathode layer contains a part or all of the electric-conductive cathode particles in accumulated state without adhesive bonding, and the cathode surface current-collecting layer is set on the surface of the electric-conductive cathode layer and contacted with it tightly. The negative electrode piece comprises an electric-conductive lithium-intercalatable anode layer which is a lithium-containing metal body and/or a layer containing a part or all of electric-conductive lithium-intercalatable anode particles in accumulated state without adhesive bonding. The peripheral edges of the positive electrode piece and/or the negative electrode piece are insulated and sealed. A lithium slurry battery module containing the no-liquid cell-core is also provided.

Cell-core for lithium slurry battery, and lithium slurry battery module

Inhibitors of Wnt signaling pathway with structures of Formula I are disclosed, together with their pharmaceutical salts. Applications of compounds of Formula I in inhibiting or modulating the Wnt signaling pathway are also disclosed. Compounds of Formula I can treat disorders caused by aberrant activation of the Wnt signaling pathway. 

Wnt signaling pathway inhibitors and therapeutic applications thereof

Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as Hreceptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by Hreceptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

[object Object]

The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Imidazopyridazine compounds

The present invention relates to the use of novel thiazolopyrimidine derivatives of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Thiazolopyrimidine compounds

Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

Pyrrolopyrazine kinase inhibitors

Pyrazolo pyrimidines

Growing community of inventors

Beijing, China

Xiaohu Zhang